Kirkwood J, Dummer R, Hauschild A, Santinami M, Atkinson V, Sileni V, Larkin J, Nyakas M, Haydon A, Dutriaux C, Schachter J, Robert C, Mortier L, Banerjee H, Haas T, Tan M, Lau M, Schadendorf D, Long G, Mandala M. Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. J of Skin [Internet]. 2021Jan.1 [cited 2024Jul.22];5(1):s2. Available from: https://jofskin.org/index.php/skin/article/view/1154